The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

Merck MRK along with partner Eisai announced data from the phase III LEAP-015 study, which evaluated blockbuster PD-1 ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction ...

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

Treating initially unresectable gastric or GEJ cancer with camrelizumab plus nab-POF led to an R0 resection rate of 75% in a phase 2 trial.